Article: FDA Panel Evaluates SSRIs, Risk Of Suicidal Thoughts.

Washington Editor

BETHESDA, Md. - Some FDA regulators believe drug companies might need to conduct large, randomized, controlled studies to ascertain whether antidepressants prompt suicide or thoughts of suicide in kids. Such opinions were aired Monday before the FDA's psychopharmacologic and pediatric advisory panels concerning the use of selective serotonin reuptake inhibitors (SSRIs) in children.

Panel members heard analyses from the FDA and a committee of experts assembled by Columbia University to review trials involving kids with major depressive disorder (MDD) and other psychiatric disorders who might take products like Zoloft, Paxil or Prozac. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!